Coherus Biosciences(CHRS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CHRS Coherus Biosciences

已收盘 04-29 16:00:00 EDT

1.74

-0.03

-1.69%

盘后1.75

+0.01+0.57%

19:54 EDT

最高1.76	最低1.70	成交量66.54万
今开1.75	昨收1.77	日振幅3.05%
总市值2.68亿	流通市值2.42亿	总股本1.54亿
成交额115.00万	换手率0.48%	流通股本1.39亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CHRS","market":"US","secType":"STK","nameCN":"Coherus Biosciences","latestPrice":1.74,"timestamp":1777492800000,"preClose":1.77,"halted":0,"volume":665403,"hourTrading":{"tag":"盘后","latestPrice":1.75,"preClose":1.74,"latestTime":"19:54 EDT","volume":6829,"amount":11970.812,"timestamp":1777506880485,"change":0.01,"changeRate":0.005747,"amplitude":0.017241},"delay":0,"changeRate":-0.016949152542372895,"floatShares":139000000,"shares":154217609,"eps":1.434343,"marketStatus":"已收盘","change":-0.03,"latestTime":"04-29 16:00:00 EDT","open":1.75,"high":1.755,"low":1.701,"amount":1149974.2841319,"amplitude":0.030508,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.434343,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1777536000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1415250000000,"exchange":"NASDAQ","adjPreClose":1.77,"preHourTrading":{"tag":"盘前","latestPrice":1.75,"preClose":1.77,"latestTime":"09:29 EDT","volume":578,"amount":1018.1900032,"timestamp":1777469399931,"change":-0.02,"changeRate":-0.011299,"amplitude":0.016949},"postHourTrading":{"tag":"盘后","latestPrice":1.75,"preClose":1.74,"latestTime":"19:54 EDT","volume":6829,"amount":11970.812,"timestamp":1777506880485,"change":0.01,"changeRate":0.005747,"amplitude":0.017241},"volumeRatio":0.698425,"impliedVol":1.4638,"impliedVolPercentile":0.5618},"requestUrl":"/m/hq/s/CHRS","defaultTab":"news","newsList":[{"id":"2618133201","title":"Coherus Oncology, Inc.盘中异动 急速跳水5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618133201","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618133201?lang=zh_cn&edition=full","pubTime":"2026-03-12 00:05","pubTimestamp":1773245115,"startTime":"0","endTime":"0","summary":"北京时间2026年03月12日00时05分，Coherus Oncology, Inc.股票出现异动，股价快速下挫5.06%。Coherus Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.84%。Coherus Oncology, Inc.公司简介：Coherus Oncology Inc是一家全方位整合的商业阶段创新型肿瘤学公司，拥有已获批的下一代PD-1抑制剂LOQTORZI以及一条包括两款针对肝癌、肺癌、头颈癌和其他癌症的中期临床候选药物在内的管线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603120005159548ecfa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603120005159548ecfa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CHRS","BK4535","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609533856","title":"Coherus Oncology, Inc.盘中异动 股价大跌5.36%报2.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533856","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609533856?lang=zh_cn&edition=full","pubTime":"2026-02-06 04:50","pubTimestamp":1770324611,"startTime":"0","endTime":"0","summary":"北京时间2026年02月06日04时50分，Coherus Oncology, Inc.股票出现波动，股价大幅下挫5.36%。Coherus Oncology, Inc.股票所在的生物技术行业中，整体跌幅为1.57%。Coherus Oncology, Inc.公司简介：Coherus Oncology Inc是一家全方位整合的商业阶段创新型肿瘤学公司，拥有已获批的下一代PD-1抑制剂LOQTORZI以及一条包括两款针对肝癌、肺癌、头颈癌和其他癌症的中期临床候选药物在内的管线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206045013a4817c0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206045013a4817c0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CHRS","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119073227","title":"Coherus BioSciences：强生将提供Pasritamig，公司将成为1B期临床试验申办方","url":"https://stock-news.laohu8.com/highlight/detail?id=1119073227","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119073227?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:45","pubTimestamp":1770212735,"startTime":"0","endTime":"0","summary":"生物技术公司Coherus BioSciences宣布，其合作伙伴强生（Janssen）将向公司提供在研疗法Pasritamig。根据协议安排，Coherus BioSciences将作为该疗法1B期临床试验的申办方，负责试验的推进与执行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","CHRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105912064","title":"Coherus BioSciences与强生各自保留其化合物全部商业权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1105912064","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105912064?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:44","pubTimestamp":1770212687,"startTime":"0","endTime":"0","summary":"Coherus BioSciences与强生公司已达成协议，双方将各自保留其研发化合物的全部商业化权利。这一安排明确了各自的知识产权归属和未来市场开发路径，为双方后续的独立商业运作奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHRS","BK4535","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101132122","title":"Coherus公布六年Jupiter-02随访结果显示Loqtorzi®联合化疗几乎使鼻咽癌的中位整体生存期增加一倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1101132122","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101132122?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:33","pubTimestamp":1765200807,"startTime":"0","endTime":"0","summary":"Coherus公布六年Jupiter-02随访结果显示，Loqtorzi®联合化疗几乎使鼻咽癌的中位整体生存期增加一倍。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4535","CHRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183845036","title":"Coherus Oncology第三季度销售额为1157.1万美元，低于IBES预期的1340万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183845036","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183845036?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:03","pubTimestamp":1763571828,"startTime":"0","endTime":"0","summary":"11月6日消息，Coherus Oncology第三季度净亏损为3553.1万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHRS","BK4535","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584196351","title":"Coherus Oncology, Inc.盘中异动 临近午盘股价大涨5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584196351","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584196351?lang=zh_cn&edition=full","pubTime":"2025-11-19 00:57","pubTimestamp":1763485057,"startTime":"0","endTime":"0","summary":"北京时间2025年11月19日00时57分，Coherus Oncology, Inc.股票出现波动，股价快速拉升5.30%。Coherus Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。Coherus Oncology, Inc.公司简介：Coherus Oncology Inc是一家全方位整合的商业阶段创新型肿瘤学公司，拥有已获批的下一代PD-1抑制剂LOQTORZI以及一条包括两款针对肝癌、肺癌、头颈癌和其他癌症的中期临床候选药物在内的管线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119005737950c9adf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119005737950c9adf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","CHRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583066737","title":"Coherus Oncology, Inc.2025财年第三财季实现净利润-44.52百万美元，同比减少314.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583066737","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583066737?lang=zh_cn&edition=full","pubTime":"2025-11-16 00:02","pubTimestamp":1763222555,"startTime":"0","endTime":"0","summary":"11月16日，Coherus Oncology, Inc.公布财报，公告显示公司2025财年第三财季净利润为-44.52百万美元，同比减少314.14%；其中营业收入为11.57百万美元，同比减少83.65%，每股基本收益为-0.30美元。从资产负债表来看，Coherus Oncology, Inc.总负债4.29亿美元，其中短期债务1.79百万美元，资产负债比为1.21，流动比率为1.24。机构评级：截至2025年11月16日，当前有3家机构对Coherus Oncology, Inc.目标价做出预测，其中目标均价为5.67美元，其中最低目标价为4.00美元，最高目标价为7.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116000328a6fbb5a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116000328a6fbb5a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CHRS","BK4139","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518783267","title":"Coherus BioSciences(CHRS.US)：2024年Q4财报实现营收5414.4万美元，前值为9152.4万美元，预期值为4388万美元；每股收益为-0.28美元，前值为-0.62美元，预期值为-0.13美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518783267","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518783267?lang=zh_cn&edition=full","pubTime":"2025-03-11 04:31","pubTimestamp":1741638703,"startTime":"0","endTime":"0","summary":"Coherus BioSciences(CHRS.US)：2024年Q4财报实现营收5414.4万美元，前值为9152.4万美元，预期值为4388万美元；每股收益为-0.28美元，前值为-0.62美元，预期值为-0.13美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11043148642742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CHRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109189574","title":"Coherus BioSciences 2024年第四季度调整后每股亏损$(0.28)，不及预期$(0.13)，销售额$5414.4万超过预期$4727.0万","url":"https://stock-news.laohu8.com/highlight/detail?id=1109189574","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109189574?lang=zh_cn&edition=full","pubTime":"2025-03-11 04:18","pubTimestamp":1741637918,"startTime":"0","endTime":"0","summary":"Coherus BioSciences  报告季度每股亏损$，低于分析师一致预期的$，减少了115.38%。与去年同期每股亏损$相比，这是一个54.84%的改善。公司报告季度销售额为$5414.4万，超过分析师一致预期的$4727.0万，高出14.54%。以上内容来自Benzinga Earnings专栏，原文如下：Coherus BioSciences  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 115.38 percent. This is a 54.84 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $54.144 million which beat the analyst consensus estimate of $47.270 million b","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Coherus BioSciences 2024年第四季度调整后每股亏损$(0.28)，不及预期$(0.13)，销售额$5414.4万超过预期$4727.0万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518227963","title":"Coherus Biosciences, Inc.盘中异动 早盘股价大涨5.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518227963","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518227963?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:43","pubTimestamp":1741614197,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时43分，Coherus Biosciences, Inc.股票出现异动，股价急速拉升5.77%。Coherus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Trevi Therapeutics, Inc.、Checkpoint Therapeutics, Inc.、Scisparc Ltd.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2346.37%、549.18%、83.46%，振幅较大的相关个股有Scisparc Ltd.、Impact Biomedical, Inc.、Trevi Therapeutics, Inc.，振幅分别为40.24%、28.59%、25.35%。Coherus Biosciences, Inc.公司简介：Coherus BioSciences Inc 是一家商业阶段的生物制药公司，利用 FDA 批准的多元化疗法组合产生的现金，资助建立免疫肿瘤学特许经营权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021431798a29fe7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021431798a29fe7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CHRS","BK4535","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517319875","title":"Coherus Biosciences, Inc.盘中异动 股价大跌5.28%报0.976美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517319875","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517319875?lang=zh_cn&edition=full","pubTime":"2025-03-07 01:20","pubTimestamp":1741281608,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日01时20分，Coherus Biosciences, Inc.股票出现波动，股价急速下跌5.28%。Coherus Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.75%。Coherus Biosciences, Inc.公司简介：Coherus BioSciences Inc 是一家商业阶段的生物制药公司，利用 FDA 批准的多元化疗法组合产生的现金，资助建立免疫肿瘤学特许经营权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307012008989ed2d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307012008989ed2d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","CHRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517698570","title":"Coherus Biosciences, Inc.盘中异动 股价大涨5.47%报1.06美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517698570","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517698570?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:03","pubTimestamp":1741118611,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时03分，Coherus Biosciences, Inc.股票出现波动，股价快速上涨5.47%。Coherus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。Coherus Biosciences, Inc.公司简介：Coherus BioSciences Inc 是一家商业阶段的生物制药公司，利用 FDA 批准的多元化疗法组合产生的现金，资助建立免疫肿瘤学特许经营权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305040331989bf850&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305040331989bf850&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CHRS","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516654568","title":"Coherus Biosciences, Inc.盘中异动 大幅跳水5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516654568","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516654568?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:10","pubTimestamp":1741025425,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时10分，Coherus Biosciences, Inc.股票出现波动，股价急速跳水5.41%。Coherus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.19%。Coherus Biosciences, Inc.公司简介：Coherus BioSciences Inc 是一家商业阶段的生物制药公司，利用 FDA 批准的多元化疗法组合产生的现金，资助建立免疫肿瘤学特许经营权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304021026a25d7f84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304021026a25d7f84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4535","CHRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514750043","title":"Coherus Biosciences, Inc.盘中异动 快速拉升5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514750043","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514750043?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:32","pubTimestamp":1740756734,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日23时32分，Coherus Biosciences, Inc.股票出现波动，股价快速拉升5.09%。Coherus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。Coherus Biosciences, Inc.公司简介：Coherus BioSciences Inc 是一家商业阶段的生物制药公司，利用 FDA 批准的多元化疗法组合产生的现金，资助建立免疫肿瘤学特许经营权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228233214989687b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228233214989687b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","CHRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514987776","title":"Coherus Biosciences, Inc.盘中异动 临近午盘股价大涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514987776","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514987776?lang=zh_cn&edition=full","pubTime":"2025-02-25 00:36","pubTimestamp":1740414967,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日00时36分，Coherus Biosciences, Inc.股票出现波动，股价急速上涨5.14%。Coherus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.06%。Coherus Biosciences, Inc.公司简介：Coherus BioSciences Inc 是一家商业阶段的生物制药公司，利用 FDA 批准的多元化疗法组合产生的现金，资助建立免疫肿瘤学特许经营权。该公司在美国销售 Neulasta 的生物仿制药，UDENYCA，并预计于 2023 年在美国推出 FDA 批准的 Humira 生物仿制药 YUSIMRY。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225003608962eb475&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225003608962eb475&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CHRS","BK4139","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512810254","title":"Coherus Biosciences, Inc.盘中异动 早盘急速跳水5.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512810254","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512810254?lang=zh_cn&edition=full","pubTime":"2025-02-20 00:05","pubTimestamp":1739981106,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日00时05分，Coherus Biosciences, Inc.股票出现异动，股价大幅下挫5.36%。Coherus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.47%。Coherus Biosciences, Inc.公司简介：Coherus BioSciences Inc 是一家商业阶段的生物制药公司，利用 FDA 批准的多元化疗法组合产生的现金，资助建立免疫肿瘤学特许经营权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220000506a24c0d6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220000506a24c0d6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CHRS","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512931101","title":"Coherus Biosciences, Inc.盘中异动 大幅下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512931101","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512931101?lang=zh_cn&edition=full","pubTime":"2025-02-19 02:10","pubTimestamp":1739902251,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日02时10分，Coherus Biosciences, Inc.股票出现异动，股价大幅下挫5.00%。Coherus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.58%。其相关个股中，Aditxt, Inc.、Solid Biosciences Inc.、Allogene Therapeutics, Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为652.29%、197.44%、164.02%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.，振幅分别为148.75%、92.00%、79.17%。Coherus Biosciences, Inc.公司简介：Coherus BioSciences Inc 是一家商业阶段的生物制药公司，利用 FDA 批准的多元化疗法组合产生的现金，资助建立免疫肿瘤学特许经营权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219021051a24adaa6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219021051a24adaa6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CHRS","BK4535","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510532973","title":"Coherus Biosciences, Inc.盘中异动 下午盘大幅下挫5.13%报1.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510532973","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510532973?lang=zh_cn&edition=full","pubTime":"2025-02-12 02:32","pubTimestamp":1739298734,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日02时32分，Coherus Biosciences, Inc.股票出现异动，股价急速下挫5.13%。Coherus Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为1.79%。其相关个股中，Omega Therapeutics, Inc.、Lipella Pharmaceuticals Inc.、Dominari Holdings Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为3092.34%、1432.04%、482.65%，振幅较大的相关个股有Omega Therapeutics, Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.，振幅分别为143.33%、72.23%、58.60%。Coherus Biosciences, Inc.公司简介：Coherus BioSciences Inc 是一家商业阶段的生物制药公司，利用 FDA 批准的多元化疗法组合产生的现金，资助建立免疫肿瘤学特许经营权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212023214a2422ead&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212023214a2422ead&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CHRS","BK4535","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510089496","title":"Coherus Biosciences, Inc.盘中异动 大幅拉升5.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510089496","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510089496?lang=zh_cn&edition=full","pubTime":"2025-02-11 03:56","pubTimestamp":1739217413,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日03时56分，Coherus Biosciences, Inc.股票出现异动，股价大幅上涨5.36%。Coherus Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.97%。Coherus Biosciences, Inc.公司简介：Coherus BioSciences Inc 是一家商业阶段的生物制药公司，利用 FDA 批准的多元化疗法组合产生的现金，资助建立免疫肿瘤学特许经营权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211035653abc9ea01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211035653abc9ea01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CHRS","BK4139","BK4535"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.coherus.com","stockEarnings":[{"period":"1week","weight":-0.0275},{"period":"1month","weight":0.0859},{"period":"3month","weight":-0.2009},{"period":"6month","weight":0.0412},{"period":"1year","weight":0.7184},{"period":"ytd","weight":0.2465}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.1224},{"period":"3month","weight":0.0234},{"period":"6month","weight":0.0469},{"period":"1year","weight":0.292},{"period":"ytd","weight":0.0437}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Coherus Oncology, Inc.于2010年9月在特拉华州注册成立。该公司是一家商业阶段的生物制药公司，专注于创新癌症治疗的研究、开发和商业化以及已获批准的生物类似物组合的商业化。该公司的战略是建立一个领先的免疫肿瘤专营权，其资金来自通过净销售美国食品和药物管理局批准的疗法的多元化组合所产生的现金。","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.044108},{"month":2,"riseRate":0.416667,"avgChangeRate":-0.013974},{"month":3,"riseRate":0.5,"avgChangeRate":0.004845},{"month":4,"riseRate":0.583333,"avgChangeRate":-0.024477},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.027386},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.017822},{"month":7,"riseRate":0.545455,"avgChangeRate":0.104665},{"month":8,"riseRate":0.818182,"avgChangeRate":0.118971},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.092992},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.062607},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.005438},{"month":12,"riseRate":0.583333,"avgChangeRate":0.04063}],"exchange":"NASDAQ","name":"Coherus Biosciences","nameEN":"Coherus BioSciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Coherus Biosciences(CHRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Coherus Biosciences(CHRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Coherus Biosciences,CHRS,Coherus Biosciences股票,Coherus Biosciences股票老虎,Coherus Biosciences股票老虎国际,Coherus Biosciences行情,Coherus Biosciences股票行情,Coherus Biosciences股价,Coherus Biosciences股市,Coherus Biosciences股票价格,Coherus Biosciences股票交易,Coherus Biosciences股票购买,Coherus Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Coherus Biosciences(CHRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Coherus Biosciences(CHRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}